{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:25:42Z","timestamp":1789424742762,"version":"build-2803163510"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:p>This scientific commentary refers to \u2018Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry\u2019 by Voigt-M\u00fcller et al. (https:\/\/doi.org\/10.1093\/brain\/awaf472).<\/jats:p>","DOI":"10.1093\/brain\/awag041","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:41:21Z","timestamp":1769690481000},"page":"701-703","source":"Crossref","is-referenced-by-count":2,"title":["Real-world treatment dynamics in spinal muscular atrophy: what the SMArtCARE registry renders visible"],"prefix":"10.1093","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-4222","authenticated-orcid":false,"given":"Kentaro","family":"Okamoto","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Ehime Prefectural Imabari Hospital , Imabari, Ehime ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026030512074841200_awag041-B1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"2026030512074841200_awag041-B2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: Final report of a phase 2, open-label, multicentre, dose-escalation study","volume":"5","author":"Finkel","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"2026030512074841200_awag041-B3","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"key":"2026030512074841200_awag041-B4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"key":"2026030512074841200_awag041-B5","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1177\/22143602241288095","article-title":"Newborn screening programs for spinal muscular atrophy worldwide in 2023","volume":"11","author":"Vr\u0161\u010daj","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"2026030512074841200_awag041-B6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/brain\/awaf472","article-title":"Treatment evolution in spinal muscular atrophy: Insights from the SMArtCARE registry","volume":"149","author":"Voigt-M\u00fcller","year":"2026","journal-title":"Brain"},{"key":"2026030512074841200_awag041-B7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12883-025-04276-4","article-title":"Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: A multicenter case series","volume":"25","author":"Svoboda","year":"2025","journal-title":"BMC Neurol"},{"key":"2026030512074841200_awag041-B8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/mus.28383","article-title":"Characteristics of patients with spinal muscular atrophy who have switched treatments: A multi-center experience in the United Kingdom","volume":"71","author":"O\u2019Reilly","year":"2025","journal-title":"Muscle Nerve"},{"key":"2026030512074841200_awag041-B9","first-page":"1","article-title":"Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy","volume":"82","author":"Zanoteli","year":"2024","journal-title":"Arq Neuropsiquiatr"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awag041\/66636967\/awag041.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/3\/701\/66636967\/awag041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/3\/701\/66636967\/awag041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:07:55Z","timestamp":1772730475000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/149\/3\/701\/8444921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":9,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,1,30]]},"published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awag041","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,1,30]]}}}